Sonnet biotherapeutics regains nasdaq minimum bid price compliance

Princeton, nj / accesswire / september 19, 2023 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has received formal notice from the listing qualifications staff of the nasdaq stock market indicating that sonnet has regained compliance with the minimum bid price requirement set forth in nasdaq listing rule 5550(a)(2). to regain compliance with the rule, the company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on september 15, 2023.
SONN Ratings Summary
SONN Quant Ranking